Palatin Technologies, Inc. (PTN)
| Market Cap | 232.20M |
| Revenue (ttm) | -267,950 |
| Net Income (ttm) | -21.87M |
| Shares Out | 236.35M |
| EPS (ttm) | -0.10 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Dividend Yield | n/a |
| Trading Day | January 21 |
| Last Price | $1.15 |
| Previous Close | $1.01 |
| Change ($) | 0.14 |
| Change (%) | 13.86% |
| Day's Open | 1.18 |
| Day's Range | 1.10 - 1.25 |
| Day's Volume | 22,706,591 |
| 52-Week Range | 0.36 - 1.25 |
CRANBURY, N.J., Dec. 15, 2020 /PRNewswire/ -- Palatin Technologies, Inc. (NYSE American: PTN), a specialized biopharmaceutical company developing first-in-class medicines based on molecules th...
Palatin Technologies (PTN) saw a big move last session, as its shares jumped 8% on the day, amid huge volumes.
Palatin Technologies, Inc. (PTN) CEO Carl Spana on Q1 2021 Results - Earnings Call Transcript
CRANBURY, N.J., Nov. 17, 2020 /PRNewswire/ -- Palatin Technologies, Inc. (NYSE American: PTN), a specialized biopharmaceutical company developing first-in-class medicines based on molecules th...
CRANBURY, N.J., Nov. 12, 2020 /PRNewswire/ -- Palatin Technologies, Inc. (NYSE American: PTN) will announce its first quarter, fiscal year 2021 operating results on Tuesday, November 17, 2020 ...
Palatin Technologies, Inc. (PTN) CEO Carl Spana on Q4 2020 Results - Earnings Call Transcript
CRANBURY, N.J., Sept. 28, 2020 /PRNewswire/ -- Palatin Technologies, Inc. (NYSE American: PTN), a specialized biopharmaceutical company developing first-in-class medicines based on molecules t...
CRANBURY, N.J., Sept. 24, 2020 /PRNewswire/ -- Palatin Technologies, Inc. (NYSE American: PTN) will announce its fourth quarter and fiscal year end 2020 operating results on Monday, September ...
CRANBURY, N.J., Sept. 10, 2020 /PRNewswire/ -- Palatin Technologies, Inc.
CRANBURY, N.J., Aug. 13, 2020 /PRNewswire/ -- Palatin Technologies, Inc.
CRANBURY, N.J., Aug. 5, 2020 /PRNewswire/ -- Palatin Technologies, Inc.
Shares of Palatin Technologies Inc. PTN, +2.50% gained 31.8% in premarket trading on Tuesday after it said it would test one of its investigational drugs as a treatment for COVID-19.
Palatin Technologies, Inc. (PTN) CEO Carl Spana on Q3 2020 Results - Earnings Call Transcript
Palatin Technologies, Inc. (PTN) CEO Carl Spana on Q2 2020 - Earnings Call Transcript
Palatin Technologies' (PTN) CEO Carl Spana on Q1 2020 Results - Earnings Call Transcript
Every 10% of market share captured by Vyleesi is likely to generate $27 million in royalties for PTN.
Palatin Technologies, Inc. (NYSEMKT:PTN) Q4 2019 Earnings Conference Call September 12, 2019 11:00 AM ET
Investors will focus on pipeline updates, when Palatin (PTN) releases fourth-quarter fiscal 2019 results.
In the latest trading session, Palatin (PTN) closed at $0.91, marking a -1.7% move from the previous day.
Is (PTN) Outperforming Other Medical Stocks This Year?
Palatin (PTN) closed the most recent trading day at $1, moving +0.37% from the previous trading session.
A high-profile analyst questioned the company's recent FDA approval.
Shares of Palatin Technologies Inc. rocketed 27% in very active premarket trading Monday, after a positive Food and Drug Administration decision on AMAG Pharmaceuticals Inc. treatment for hypo...
The demanded phase I trial showed consistent results compared to the previous trials and AMAGs CEO is: "fairly optimistic about the approval ability" of Vyleesi.
Two hope to pick up additional indications for existing blockbuster drugs, while another could score a big victory for a new drug.
Palatin Technologies' (PTN) CEO Carl Spana on Q3 2019 Results - Earnings Call Transcript
Palatin Technologies (PTN) shares rose nearly 6% in the last trading session, amid huge volumes.
About PTN
Palatin Technologies, a specialized biopharmaceutical company, develops targeted receptor-specific therapeutics for the treatment of various diseases in the United States. The company's lead product is Vyleesi, a melanocortin receptor agonist for the treatment of premenopausal women with acquired, generalized hypoactive sexual desire disorder. It is also developing oral PL8177, a selective melanocortin receptor (MCr) 1 agonist peptide that has completed Phase I clinical trial for the treatment of inflammatory bowel diseases; and systemic PL8177... [Read more...]
| Industry Biotechnology | IPO Date Oct 28, 1993 |
| CEO Carl Spana | Employees 20 |
| Stock Exchange NYSEAMERICAN | Ticker Symbol PTN |
Analyst Forecasts
According to 3 analysts, the average rating for PTN stock is "Strong Buy." The 12-month stock price forecast is 2.33, which is an increase of 102.61% from the latest price.